Franklin Street Advisors’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Franklin Street Advisors’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-96,429	Closed	-$34K	–	171
2018 Q2	$34K	Hold	96,429	–	–	0.01%	158
2018 Q1	$145K	Hold	96,429	–	–	0.02%	156
2017 Q4	$137K	Sell	96,429 -2,800	-3%	-$4.6K	0.02%	160
2017 Q3	$227K	Hold	99,229	–	–	0.04%	138
2017 Q2	$134K	Buy	99,229 +40,000	+68%	+$57.8K	0.02%	144
2017 Q1	$127K	Sell	59,229 -107,504	-64%	-$404K	0.02%	152
2016 Q4	$735K	Hold	166,733	–	–	0.13%	107
2016 Q3	$809K	Sell	166,733 -2,258	-1%	-$10.3K	0.15%	108
2016 Q2	$558K	Buy	168,991 +109,491	+184%	+$413K	0.11%	124
2016 Q1	$211K	Buy	+59,500	New	+$307K	0.04%	201

Other funds holding ARLZ

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Franklin Street Advisors's ARLZ Position: Q3 2018 in Review

Franklin Street Advisors sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 96,429 shares — an estimated $34K sold.

Franklin Street Advisors first reported a position in ARLZ in Q1 2016 and held it in 10 quarters. The position peaked at $809K in Q3 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

Franklin Street Advisors reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Franklin Street Advisors sold 96,429 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $34K.
Franklin Street Advisors first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 10 quarters.
Franklin Street Advisors's Aralez Pharmaceuticals Inc. position peaked at $809K in Q3 2016.
4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Franklin Street Advisors's 13F filing for Q3 2018, filed 5 Oct 2018.